Higher values of R2* (the magnetic resonance transverse relaxation rate) found in the substantia nigra (SN) likely reflect greater iron content and are associated with worse long-term outcomes after stroke, according to a study published online March 12 i
Shield Therapeutics has revealed that the US Food and Drug Administration will make a decision on its application to market Feraccru in the US by July 27 next year.